Autori: Bertini E

Filtra

Data

Body mass index in type 2 spinal muscular atrophy: a longitudinal study

Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy

Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes

Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies

SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples

Different trajectories in upper limb and gross motor function in spinal muscular atrophy

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy

North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up

Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

Type I SMA “new natural history”: long-term data in nusinersen-treated patients

Torna in alto